{"id":"lopinavir-ritonavir-zidovudine-lamivudine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"20-40","effect":"Lipid abnormalities (elevated cholesterol/triglycerides)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"1-3","effect":"Pancreatitis"},{"rate":"5-15","effect":"Peripheral neuropathy (from zidovudine)"},{"rate":"5-10","effect":"Anemia (from zidovudine)"},{"rate":"10-20","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL26318","moleculeType":"Small molecule","molecularWeight":"267.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the maturation of infectious viral particles. Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit the reverse transcriptase enzyme, blocking HIV RNA conversion to DNA. Together, this triple therapy targets multiple steps of the HIV replication cycle.","oneSentence":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:10.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00621166","phase":"PHASE2","title":"Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-06","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT01125696","phase":"PHASE2","title":"Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-05","conditions":"HIV, Hepatitis B","enrollment":45},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT02231281","phase":"PHASE3","title":"Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults","status":"UNKNOWN","sponsor":"Yongtao Sun, MD, PhD","startDate":"2014-08","conditions":"Acute HIV Infection","enrollment":65},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT00719602","phase":"EARLY_PHASE1","title":"Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2009-08","conditions":"HIV Infections, Malaria","enrollment":105},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00753324","phase":"PHASE4","title":"Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-05","conditions":"HIV Infections","enrollment":284},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00834457","phase":"PHASE2, PHASE3","title":"A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe","status":"COMPLETED","sponsor":"Parirenyatwa Hospital","startDate":"2007-06","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":49},{"nctId":"NCT00143689","phase":"PHASE4","title":"NRTI-Sparing Pilot Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2002-04","conditions":"HIV, Mitochondrial Toxicity","enrollment":13},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00865475","phase":"PHASE4","title":"Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, HIV Infections","enrollment":38},{"nctId":"NCT01772940","phase":"PHASE4","title":"Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2008-12","conditions":"HIV-1 Infection","enrollment":425},{"nctId":"NCT00050908","phase":"","title":"Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00424814","phase":"PHASE2, PHASE3","title":"Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-03","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00192621","phase":"PHASE4","title":"Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections, Dyslipidemias, Glucose Metabolism Disorders","enrollment":50},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00405925","phase":"PHASE3","title":"FREE Study: Efficacy and Toxicity of Trizivir","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2003-03","conditions":"HIV Infections","enrollment":207},{"nctId":"NCT00164736","phase":"PHASE3","title":"Breastfeeding, Antiretroviral, and Nutrition Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"HIV Infections","enrollment":2369},{"nctId":"NCT00385645","phase":"PHASE4","title":"Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2006-05","conditions":"HIV Infections","enrollment":255},{"nctId":"NCT00966160","phase":"PHASE3","title":"CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1999-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":215},{"nctId":"NCT00234923","phase":"PHASE3","title":"Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-08","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT00043953","phase":"PHASE2","title":"Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-08","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00080522","phase":"NA","title":"Strategies for Delivering Anti-HIV Therapy in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":813},{"nctId":"NCT00075231","phase":"PHASE2","title":"A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-12","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00162643","phase":"PHASE4","title":"PI Vs. NNRTI Based Therapy for HIV Advanced Disease","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2004-12","conditions":"Acquired Immunodeficiency Syndrome","enrollment":300},{"nctId":"NCT00122226","phase":"PHASE4","title":"MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2003-01","conditions":"HIV Infections, HIV-Associated Lipodystrophy Syndrome","enrollment":50},{"nctId":"NCT00139178","phase":"PHASE4","title":"Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.","status":"COMPLETED","sponsor":"Danish HIV Research Group","startDate":"2004-03","conditions":"HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABORTION SPONTANEOUS"},{"count":1,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lopinavir/ritonavir + zidovudine + lamivudine","genericName":"Lopinavir/ritonavir + zidovudine + lamivudine","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}